Document is current
Any future updates will be listed below
-
Authors
Møller, Pål
Ahadova, Aysel
Kloor, Matthias
Seppälä, Toni T.
Burn, John
Haupt, Saskia
Macrae, Finlay
Dominguez-Valentin, Mev
Möslein, Gabriela
Lindblom, Annika
sunde, Lone
Winship, Ingrid
Capella, Gabriel
Monahan, Kevin
Buchanan, Daniel D.
Evans, D. Gareth
Hovig, Eivind
Sampson, Julian R.
-
Funding
Funding for this research was provided by:
Syöpäsäätiö
Sigrid Juselius Foundation
Jane and Aatos Erkko Foundation
Relander Foundation
Research Council of Finland
Finland State Research Funding through Pirha and to HUS
Manchester National Institute for Health Research (NIHR) Biomedical Research Centre (IS-BRC-1215-20007)
- License Information
-
More Information
Article History
Received: 19 December 2024
Accepted: 19 January 2025
First Online: 23 January 2025
Declarations
:
: Not applicable.
: Not applicable.
: T.T.S. reports consultation fees from Mehiläinen, Nouscom, Orion Pharma, Amgen, and Tillots Pharma, being a co-owner and CEO of Healthfund Finland Ltd., and a position in the Clinical Advisory Board and as a minor shareholder of Lynsight Ltd. M.D.V. is advisor of Nouscom. Other authors declare that they have no conflicts of interest. All other authours declare no conflict of interest relevant to the current paper.
